New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

By | August 21, 2021
Immunotherapy agents that inhibit the molecules PD1, PD-L1 or CTLA-4 have become widely used in clinical practice to treat non-small cell lung cancer, or NSCLC.